Should I Buy RZLT? RZLT 2026 Analysis

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.850

1 Day change

-4.68%

52 Week Range

11.460

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Rezolute Inc (RZLT) is not a strong buy for a beginner, long-term investor at this moment. While there are some positive developments, such as the FDA's interest in the sunRIZE program and an upgraded analyst rating, the stock's financial performance, technical indicators, and lack of significant trading signals suggest a cautious approach. The pre-market price drop and bearish moving averages further support holding off on immediate investment.

Technical Analysis

The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral at 73.005, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading below key resistance levels (R1: 3.39, R2: 3.713) and near its pivot point (2.867). This suggests limited immediate upside potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market. However, the implied volatility is high (124.24), suggesting significant uncertainty and potential risk.

Technical Summary

Sell

Buy

Positive Catalysts

FDA's interest in the sunRIZE program despite previous endpoint failure.
Analyst upgrade by Wedbush with a price target increase to $5, citing potential benefits of ersodetug in congenital hyperinsulinism.

Neutral/Negative Catalysts

Pre-market price drop of -3.08%, indicating weak short-term sentiment.
Bearish moving averages and limited upside potential based on technical indicators.
No significant hedge fund or insider trading activity, suggesting a lack of strong institutional confidence.

Financial Performance

In Q2 2026, the company reported no revenue growth (0% YoY) and a net income loss of -$22.77 million, which improved by 44.78% YoY. EPS remained negative at -0.22. Overall, financials indicate a company still in a challenging growth phase.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wedbush upgraded Rezolute to Outperform from Neutral, raising the price target to $5 from $2. The upgrade is based on FDA feedback and the potential of ersodetug in addressing unmet medical needs in congenital hyperinsulinism. However, the valuation includes only a modest 30% probability of success for the program.

9 Analyst Rating

Wall Street analysts forecast RZLT stock price to rise

5 Buy

4 Hold

0 Sell

Moderate Buy

Current: 2.850

Low

Averages

6.29

High

Current: 2.850

Low

Averages

6.29

High

Wedbush

Neutral

Outperform

upgrade

$2 -> $5

AI Analysis

2026-03-25

Reason

Wedbush

Price Target

$2 -> $5

AI Analysis

2026-03-25

upgrade

Neutral

Outperform

Reason

Wedbush upgraded Rezolute to Outperform from Neutral with a price target of $5, up from $2.

Wedbush

Yun Zhong

Neutral

Outperform

upgrade

$2 -> $5

2026-03-25

Reason

Wedbush

Yun Zhong

Price Target

$2 -> $5

2026-03-25

upgrade

Neutral

Outperform

Reason

As previously reported, Wedbush analyst Yun Zhong upgraded Rezolute to Outperform from Neutral with a price target of $5, up from $2, based on the update following a Type B meeting with the Food and Drug Administration to discuss the regulatory pathway for ersodetug in congenital hyperinsulinism. The FDA encouraged Rezolute to submit available data from both the randomized, double-blind, placebo-controlled portion of the pivotal Phase 3 sunRIZE study and the ongoing open-label extension portion for an independent evaluation by the FDA. Wedbush sees the FDA's feedback as showing the agency's recognition of both an unmet medical need in congenital HI and potential benefit that ersodetug can bring to patients. The firm has added the congenital HI program back to its valuation, although with a modest 30% probability of success and only revenue in the U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RZLT

Unlock Now

RZLT Should I Buy

RZLT Should I Buy

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch